Wednesday, 14 May 2008

Phentolamine mesylate: Novalar Pharma got approval from USFDA

Novalar Pharma a dental specialty pharmaceutical company, announced that the USFDA has granted marketing approval for OraVerse (Phentolamine mesylate). OraVerse is the pharmaceutical agent indicated for the reversal of softtissue anaesthesia and the associated functional deficits resulting from a local dental aesthetic. Novalar is establishing a specialty direct sales force to launch OraVerse in late 2008.

Posted by ADKS at 12:42 pm

web page statistics
Disclaimer: "IP Pharma Doc" blog is published for information purpose only. "IP Pharma Doc" blog contains no legal advice. I assume no legal responsibility for the views/information expressed here. “IP Pharma Doc” blog is my personal website and not edited by my employer, accordingly, no part of my blog should be attributed to my employer. All information on the present blog should be double checked for its accuracy and applicability. © Dr. Sarwal (2007)
 
eXTReMe Tracker